Myocardial infarction: Cardioprotection by erythropoietin

Methods in Molecular Biology

Volumn 982, Issue , 2013, Pages 265-302

  Talan, Mark I ^a   Latini, Roberto ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cardiac; Cardiomyocytes; Clinical trials; Heart; Ischemia; Ischemia reperfusion

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ARTICLE; CORONARY ARTERY LIGATION; DRUG EFFICACY; DRUG RESEARCH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; SINGLE DRUG DOSE; ANIMAL; DRUG EFFECT; HEART MUSCLE CELL;

ANIMALS; ERYTHROPOIETIN; HUMANS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; REPERFUSION INJURY;

EID: 84883467045     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-308-4_17     Document Type: Article

References (68)

1. Bogoyevitch MA (2004) An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63(2):208-216, Review
2. Koul D, Dhar S, Chen-Scarabelli C, Guglin M, Scarabelli TM (2007) Erythropoietin: new horizon in cardiovascular medicine. Recent Pat Cardiovasc Drug Discov 2(1):5-12, Review
3. Riksen NP, Hausenloy DJ, Yellon DM (2008) Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 29(5):258-267, Review
4. Latini R, Brines M, Fiordaliso F (2008) Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 13(4):415-423, Review
5. Vogiatzi G, Briasoulis A, Tousoulis D, Papageorgiou N, Stefanadis C (2010) Is there a role for erythropoietin in cardiovascular disease? Expert Opin Biol Ther 10(2):251-264, Review
6. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH (2006) Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 48(11):2161-2167, Epub 2006 Nov 9. Review
7. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N (2003) Erythropoietin protects cardiac myocytes from hypoxiainduced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308(4): 990-994
8. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 100(20): 11612-11617
9. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI (2005) Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 19(4): 243-250
10. Moon C, Krawczyk M, Lakatta EG, Talan MI (2006) Therapeutic effectiveness of a single vs. multiple doses of erythropoietin after experimental myocardial infarction in rats. Cardiovasc Drugs Ther 20(4): 245-251
11. Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, Sollott SJ, Lakatta EG, Talan MI (2006) Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316(3): 999-1005
12. Ahmet I, Tae HJ, Juhaszova M, Riordon DR, Boheler KR, Sollott SJ, Brines M, Cerami A, Lakatta EG, Talan MI (2011) A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med 17(3-4):194-200. doi: 10.2119/molmed.2010. 00235
13. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112(7): 999-1007
14. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46(1): 125-133
15. Hale SL, Sesti C, Kloner RA (2005) Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 46(2): 211-215
16. Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M, Tsukamoto O, Okada K, Koyama H, Komamura K, Takashima S, Shinozaki Y, Mori H, Shiraga M, Kitakaze M, Hori M (2006) Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 48(1):176-184, Epub 2006 Jun 2
17. Chua S, Leu S, Lin YC, Sheu JJ, Sun CK, Chung SY, Chai HT, Lee FY, Kao YH, Wu CJ, Chang LT, Ko SF, Yip HK (2011) Early erythropoietin therapy attenuates remodeling and preserves function of left ventricle in porcine myocardial infarction. J Investig Med 59(3): 574-586
18. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802-4806
19. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ (2004) Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiacfibroblasts. J Biol Chem 279: 20655-20662
20. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C (2004) Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22: 63-69
21. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2004) Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44: 473-479
22. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, Abel ED, Xenocostas A, Kvietys PR (2005) Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 65: 719-727
23. Hirata A, Minamino T, Asanuma H, Sanada S, Fujita M, Tsukamoto O, Wakeno M, Myoishi M, Okada K, Koyama H, Komamura K, Takashima S, Shinozaki Y, Mori H, Tomoike H, Hori M, Kitakaze M (2005) Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol- 3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 19: 33-40
24. Xu B, Dong GH, Liu H, Wang YQ, Wu HW, Jing H (2005) Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappa B. Ann Clin Lab Sci 35: 161-168
25. Bullard AJ, Govewalla P, Yellon DM (2005) Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100: 397-403
26. Kristensen J, Maeng M, Rehling M, Berg JS, Mortensen UM, Nielsen SS, Nielsen TT (2005) Lack of acute cardioprotective effect from pre-ischaemic erythropoietin administration in a porcine coronary occlusion model. Clin Physiol Funct Imaging 25: 305-310
27. Liu X, Xie W, Liu P, Duan M, Jia Z, Li W, Xu J (2006) Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 78: 2255-2264
28. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Ohori K, Takahashi A, Shimamoto K (2006) Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol 291:H748-H755
29. Olea FD, Vera Janavel G, De Lorenzi A, Cuniberti L, Yannarelli G, Cabeza Meckert P, Cearras M, Laguens R, Crottogini A (2006) High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol 47: 736-741
30. Liu X, Zhou Z, Feng X, Jia Z, Jin Y, Xu J (2006) Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats. Postgrad Med J 82: 588-593
31. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch WJ (2007) Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 293:H60-H68
32. Baker JE, Kozik D, Hsu AK, Fu X, Tweddell JS, Gross GJ (2007) Darbepoetin-alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms. J Cardiovasc Pharmacol 49: 337-345
33. Toma C, Letts DP, Tanabe M, Gorcsan J III, Counihan PJ (2007) Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. J Mol Cell Cardiol 43: 130-136
34. Singh D, Kolarova JD, Wang S, Ayoub IM, Gazmuri RJ (2007) Myocardial protection by erythropoietin during resuscitation from ventricularfibrillation. Am J Ther 14: 361-368
35. Boucher M, Pesant S, Lei YH, Nanton N, Most P, Eckhart AD, Koch WJ, Gao E (2008) Simultaneous administration of insulin-like growth factor-1 and darbepoetin-alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clin Transl Sci 1: 13-20
36. Prunier F, Pottier P, Clairand R, Mercier A, Hajjar RJ, Planchon B, Furber A (2009) Chronic erythropoietin treatment decreases post-infarct myocardial damage in rats without venous thrombogenic effect. Cardiology 112: 129-134
37. Shan X, Xu X, Cao B, Wang Y, Guo L, Zhu Q, Li J, Que L, Chen Q, Ha T, Li C, Li Y (2009) Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury. Int J Cardiol 134: 384-392
38. Doue T, Ohtsuki K, Ogawa K, Ueda M, Azuma A, Saji H, Strauss HW, Matsubara H (2008) Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: assessment of infarct size with 99mTcannexin V. J Nucl Med 49: 1694-1700
39. Huang CH, Hsu CY, Tsai MS, Wang TD, Chang WT, Chen WJ (2008) Cardioprotective effects of erythropoietin on post-resuscitation myocardial dysfunction in appropriate therapeutic windows. Crit Care Med 36: S467-S473
40. Burger D, Xiang F, Hammoud L, Lu X, Feng Q (2009) Role of heme oxygenase-1 in the cardioprotective effects of erythropoietin during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 296:H84-H93
41. Burger DE, Xiang FL, Hammoud L, Jones DL, Feng Q (2009) Erythropoietin protects the heart from ventricular arrhythmia during ischemia and reperfusion via neuronal nitricoxide synthase. J Pharmacol Exp Ther 329: 900-907
42. French CJ, Zaman AK, Sobel BE (2009) Failure of erythropoietin to render jeopardized ischemic myocardium amenable to incremental salvage by early reperfusion. Coron Artery Dis 20: 295-299
43. Schlecht-Bauer D, Antier D, Machet MC, Hyvelin JM (2009) Short- and long-term cardioprotective effect of darbepoetin-alpha: role of Bcl-2 family proteins. J Cardiovasc Pharmacol 54: 223-231
44. Tamareille S, Ghaboura N, Treguer F, Khachman D, Croué A, Henrion D, Furber A, Prunier F (2009) Myocardial reperfusion injury management: erythropoietin compared with postconditioning. Am J Physiol Heart Circ Physiol 297:H2035-H2043
45. Miki T, Miura T, Hotta H, Tanno M, Yano T, Sato T, Terashima Y, Takada A, Ishikawa S, Shimamoto K (2009) Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin- induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes 58: 2863-2872
46. Hotta H, Miura T, Miki T, Togashi N, Maeda T, Kim SJ, Tanno M, Yano T, Kuno A, Itoh T, Satoh T, Terashima Y, Ishikawa S, Shimamoto K (2010) Angiotensin II type 1 receptormediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circ Res 106: 129-132
47. Treguer F, Donal E, Tamareille S, Ghaboura N, Derumeaux G, Furber A, Prunier F (2010) Speckle tracking imaging improves in vivo assessment of EPO-induced myocardial salvage early after ischemia-reperfusion in rats. Am J Physiol Heart Circ Physiol 298:H1679-H1686
48. Shen Y, Wang Y, Li D, Wang C, Xu B, Dong G, Huang H, Jing H (2010) Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. Transplant Proc 42: 1595-1597
49. Stein A, Knödler M, Makowski M, Kühnel S, Nekolla S, Keithahn A, Weidl E, Groha P, Schürmann M, Saraste A, Botnar R, Oostendorp RA, Ott I (2010) Local erythropoietin and endothelial progenitor cells improve regional cardiac function in acute myocardial infarction. BMC Cardiovasc Disord 10:43
50. Yano T, Miki T, Tanno M, Kuno A, Itoh T, Takada A, Sato T, Kouzu H, Shimamoto K, Miura T (2011) Hypertensive hypertrophied myocardium is vulnerable to infarction and refractory to erythropoietin-induced protection. Hypertension 57: 110-115
51. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC (1998) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 64(4): 412-423
52. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8(8): 495-505
53. Tang YD, Hasan F, Giordano FJ, Pfau S, Rinder HM, Katz SD (2009) Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial. Am Heart J 158(6): 941-947
54. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin-alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20(2): 135-141
55. Liem A, van de Woestijne AP, Bruijns E, Roeters van Lennep HW, de Boo JA, van Halteren HK, van Es TP, Jukema JW, van der Laarse A, Zwinderman AH, van Veldhuisen DJ (2009) Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 131(2):285-287, Epub 2007 Nov 1
56. Binbrek AS, Mittal B, Rao KN, Sobel BE (2007) The potential of erythropoietin for conferring cardioprotection complementing reperfusion. Coron Artery Dis 18(7):583-585, Review
57. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE (2009) Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 104(8): 1035-1040
58. Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y, Kobayashi Y, Takeyama Y, Kobayashi N, Yoshimura N, Akazawa K, Aizawa Y, EPO/AMI-I Pilot Study Researchers (2010) Singledose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction- randomized controlled pilot trial of EPO/AMI-1 study. Circ J 74(7): 1415-1423
59. Yoshimura N, Toba K, Ozawa T, Aizawa Y, Hosoya T (2010) A novel program to accurately quantify infarction volume by (99 m)Tc MIBI SPECT, and its application for re-analyzing the effect of erythropoietin administration in patients with acute myocardial infarction. Circ J 74(12): 2741-2743
60. Belonje AM, Voors AA, van Gilst WH, Anker SD, Slart RH, Tio RA, Zijlstra F, van Veldhuisen DJ, HEBE III investigators (2008) Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 155(5): 817-822
61. Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, van't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ, HEBE III Investigators (2010) A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 31(21): 2593-2600
62. Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A, REVIVAL-3 Study Investigators (2010) Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 3(5): 408-413
63. Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M, Nakahara Y, Nakamura T, Matsubara H (2010) Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 74(11): 2365-2371
64. Melloni C, Rao SV, Povsic TJ, Melton L, Kim RJ, Kilaru R, Patel MR, Talan M, Ferrucci L, Longo DL, Lakatta EG, Najjar SS, Harrington RA (2010) Design and rationale of the reduction of infarct expansion and ventricular remodeling with erythropoietin after large myocardial infarction (REVEAL) trial. Am Heart J 160(5):795-803, e2
65. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA, REVEAL Investigators (2011) Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 305(18): 1863-1872
66. Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C, Campanelli R, Bertoletti A, De Ferrari GM, Klersy C, Angoli L, Bramucci E, Marinoni B, Ferlini M, Moretti E, Raisaro A, Repetto A, Schwartz PJ, Tavazzi L (2011) High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 147(1): 124-131
67. Andreotti F, Agati L, Conti E, Santucci E, Rio T, Tarantino F, Natale L, Berardi D, Mattatelli A, Musumeci B, Bonomo L, Volpe M, Crea F, Autore C (2009) Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). J Thromb Thrombolysis 28(4): 489-495
68. Ahmet I, Lakatta EG, Talan MI (2011) Therapeutic window for cardioprotection by recombinant human erythropoietin (rhEPO) in the rat model of ischemia-reperfusion: implications for clinical trial design. AHA 2011, Abstract